Form 4: Zimmer Biomet Executive Paul A. Stellato Reports Stock Transactions

Paul A. Stellato, VP, Controller & CAO of Zimmer Biomet Holdings, Inc., reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On June 1, 2024, Paul A. Stellato, VP, Controller & CAO of Zimmer Biomet Holdings, Inc., had restricted stock units (RSUs) vest.
• Mr. Stellato acquired 627 shares of common stock upon the vesting of these RSUs.
• Simultaneously, 197 shares were withheld by the company to satisfy tax obligations at a price of $114.47 per share.
• Following these transactions, Mr. Stellato directly owns 1,382 shares of Zimmer Biomet Holdings, Inc. common stock and 626 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and stock transactions, with no inherent positive or negative implications for the company's overall outlook.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It allows investors to monitor insider activity, which can sometimes provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies like Zimmer Biomet, similar to filings made by executives at competitors such as Stryker (SYK) and Johnson & Johnson (JNJ).
• The vesting of RSUs is a common form of executive compensation, aligning management's interests with those of shareholders, as seen in similar compensation packages at Medtronic (MDT) and Smith & Nephew (SNN).

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation arrangements.
• Shareholders can monitor these filings to gain insights into executive compensation and ownership.

Key Dates